Last reviewed · How we verify
Placebo for Azilsartan Medoxomil
This is a placebo control with no active pharmacological mechanism.
This is a placebo control with no active pharmacological mechanism. Used for Control arm in phase 3 trials for azilsartan medoxomil (angiotensin II receptor antagonist for hypertension).
At a glance
| Generic name | Placebo for Azilsartan Medoxomil |
|---|---|
| Sponsor | Arbor Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Placebo is an inert substance used as a control in clinical trials to establish the efficacy of the active drug (azilsartan medoxomil) through comparison. It contains no active pharmaceutical ingredient and produces no direct therapeutic effect beyond potential placebo response.
Approved indications
- Control arm in phase 3 trials for azilsartan medoxomil (angiotensin II receptor antagonist for hypertension)
Common side effects
Key clinical trials
- An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension (PHASE3)
- A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years With Hypertension (PHASE3)
- Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension (PHASE3)
- Effect of Azilsartan on Aldosterone in Postmenopausal Females (NA)
- Azilsartan Medoxomil (TAK-491) Compared to Placebo in Korean Adults With Hypertension (PHASE3)
- Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin in Participants With Hypertension and Diabetes (PHASE3)
- A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone (PHASE3)
- Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension. (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for Azilsartan Medoxomil CI brief — competitive landscape report
- Placebo for Azilsartan Medoxomil updates RSS · CI watch RSS
- Arbor Pharmaceuticals, Inc. portfolio CI